title: Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: a three year study of radiographic progression, renal function, and arterial hypertension.
abstract: OBJECTIVE
  To compare the three year safety and efficacy of cyclosporin and parenteral gold in the treatment of early, active, severe rheumatoid arthritis (RA), and to study the reversibility of cyclosporin associated renal dysfunction in patients who discontinued cyclosporin treatment.
  
  
  METHODS
  The patients continued to receive cyclosporin or parenteral gold in an 18 month open extension to an 18 month randomised, parallel group study. The main efficacy variable was blinded evaluation of radiographic progression of joint damage. Safety variables included serum creatinine, calculated creatinine clearance, and blood pressure.
  
  
  RESULTS
  Radiographic progression during follow up was similar in both groups. About 60% of the patients in the intention to treat groups (n=272) and about half of the patients in the completer groups (n=114) had definite radiographic progression in joint damage (increases >6 in the Larsen-Dale score), and about one in three also had substantial progression (>18 increase in Larsen-Dale score). Both systolic and diastolic blood pressure were significantly increased in the cyclosporin group compared with the gold group, and 12/139 (9%) versus 3/139 (2%) (p=0.03) had notably raised blood pressure. The mean serum creatinine increased by 28% at the treatment end point in the cyclosporin group as compared with 7% in the gold group. The mean calculated creatinine clearance was reduced by 16% and increased by 1% in the cyclosporin and gold groups, respectively, at the end of the study. At the final follow up visit after discontinuation of cyclosporin (at least three months after treatment was stopped) the mean serum creatinine was increased by 15% and creatinine clearance reduced by 16%. Sustained increases in serum creatinine at this post-treatment end point were mostly seen in patients with a raised serum creatinine during treatment of at least 50%.
  
  
  CONCLUSIONS
  Three year changes in radiographic damage during cyclosporin and parenteral gold were similar in patients with early, active RA. Abnormal renal function and raised blood pressure were often seen in the cyclosporin treated patients.
authors: Oslo City Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway. t.k.kvien@ioks.uio.no
authors: T K
authors: TK
authors: Kvien
authors: H K
authors: HK
authors: Zeidler
authors: P
authors: P
authors: Hannonen
authors: F A
authors: FA
authors: Wollheim
authors: O
authors: O
authors: Førre
authors: I
authors: I
authors: Hafström
authors: J P
authors: JP
authors: Kaltwasser
authors: M
authors: M
authors: Leirisalo-Repo
authors: B
authors: B
authors: Manger
authors: L
authors: L
authors: Laasonen
authors: H
authors: H
authors: Prestele
authors: P
authors: P
authors: Kurki
mesh_terms: D000203:Activities of Daily Living; D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000473:pathology / Q000534:rehabilitation; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D006233:Persons with Disabilities; D005260:Female; D006052:Gold Sodium Thiomalate / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007267:Injections; D007674:Kidney Diseases / Q000139:chemically induced; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D006052:Gold Sodium Thiomalate; D016572:Cyclosporine; D003404:Creatinine